GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wanbury Ltd (BOM:524212) » Definitions » YoY EBITDA Growth

Wanbury (BOM:524212) YoY EBITDA Growth : 19.03% (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Wanbury YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Wanbury's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 19.03%.

Wanbury's EBITDA per Share for the three months ended in Sep. 2024 was ₹6.59.

Wanbury YoY EBITDA Growth Historical Data

The historical data trend for Wanbury's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wanbury YoY EBITDA Growth Chart

Wanbury Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 326.71 -81.75 328.91 -79.49 314.01

Wanbury Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 185.89 224.59 271.10 -16.38 19.03

Wanbury YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Wanbury's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (A: Mar. 2024 )
=(EBITDA per Share (A: Mar. 2024 )-EBITDA per Share (A: Mar. 2023 ))/ | EBITDA per Share (A: Mar. 2023 ) |
=(29.751-7.186)/ | 7.186 |
=314.01 %

Wanbury's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(6.585-5.532)/ | 5.532 |
=19.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wanbury YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Wanbury's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Wanbury Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wanbury Ltd (BOM:524212) » Definitions » YoY EBITDA Growth
Comparable Companies
NSE:MADHAVBAUG BOM:524731 BOM:533543 BOM:500009 NSE:PAR BOM:532408 BOM:524654 BOM:530163 BOM:541096 BOM:530477 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
WANBURY:India
Address
BSEL Techpark, B Wing, 10th Floor, Sector 30-A, Opposite Vashi Railway Station, Vashi, Navi Mumbai, MH, IND, 400703
Website
https://www.wanbury.com
Wanbury Ltd is engaged in the business of pharmaceutical and related activities including research. Some of the company products are Cpink 50mg table, Rabiplus capsules, Folinine softule, etc. The company has one segment of activity namely Pharmaceuticals. It generates revenue from a contract with customers from the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.

Wanbury Headlines

No Headlines